ArticleBiotechnology letters2026
Metabolic unlocking of lycopene accumulation in the oleaginous yeast Rhodotorula toruloides.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lycopene is a high-value carotenoid with broad applications in the food, pharmaceutical, and cosmetic industries. The oleaginous yeast Rhodotorula toruloides naturally synthesizes mixed carotenoids but fails to accumulate lycopene, primarily due to the bifunctional activity of lycopene cyclase/phytoene synthase Car2, which efficiently converts lycopene into downstream cyclic carotenoids. Here, we engineered R. toruloides for efficient lycopene production using a combinatorial strategy that includes pathway blocking, heterologous enzyme screening, precursor enhancement, and fermentation optimization. CRISPR/Cas9-mediated CAR2 knockout abolished endogenous phytoene synthesizing and lycopene cyclizing activities. Heterologous complementation with exogenous phytoene synthase (CrtB) restored phytoene biosynthesis, and the resultant loss of cyclase activity blocked lycopene cyclization, facilitating robust intracellular lycopene accumulation. Screening three heterologous phytoene synthases identified EgCrtB from Euglena gracilis as the superior enzyme. Co-overexpression of endogenous rate-limiting enzymes involved in the mevalonate pathway further boosted precursor supply. Combined with nitrogen-limited cultivation, which synergistically enhanced lycopene accumulation, the final engineered strain achieved a lycopene content of 0.74 mg/g DCW and a titer of 7.24 mg/L. This work verifies that metabolic pathway modification combined with fermentation regulation can effectively drive lycopene synthesis and accumulation in R. toruloides, offering an early-stage proof-of-concept for further advancing lycopene bioproduction in oleaginous yeast.
Indexed as
Identifiers
42825966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.